Combining Dinutuximab with ALT-803 (IL-15 Superagonist) Significantly Improves the Activity of Ex Vivo Expanded Natural Killer Cells Against GD2+ Pediatric Solid Tumors (ST)

Authors

Gaurav Nayyar, New York Medical College
Yaya Chu, New York Medical CollegeFollow
Nang Kham Su, New York Medical College
Jeremy Rosenblum, New York Medical CollegeFollow
Hing C. Wong
Dean LeeFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty, Student, Resident/Fellow

Document Type

Abstract

Publication Date

3-2018

Journal Title

Biology of Blood and Marrow Transplantation

Department

Pediatrics

Second Department

Health Behavior and Community Health

Disciplines

Medicine and Health Sciences

Recommended Citation

Nayyar, G., Chu, Y., Su, N., Rosenblum, J., Wong, H. C., Lee, D., & Cairo, M. S. (2018). Combining Dinutuximab with ALT-803 (IL-15 Superagonist) Significantly Improves the Activity of Ex Vivo Expanded Natural Killer Cells Against GD2+ Pediatric Solid Tumors (ST). Biology of Blood and Marrow Transplantation, 24 (3 Suppl.1), S420-S421. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/376